Detalhe da pesquisa
1.
Outcomes and Health Care Service Use in Adults 50 Years or Older With and Without Multiple Sclerosis: A 6-Year Observational Analysis.
Int J MS Care
; 25(2): 56-62, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36923575
2.
Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data.
Mult Scler Relat Disord
; 77: 104866, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37487345
3.
Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation.
Front Neurol
; 14: 1319869, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38107636
4.
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
Mult Scler Relat Disord
; 80: 105092, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37931489
5.
Perceptions and Preferences Regarding Multiple Sclerosis Research Among Racial and Ethnic Groups.
Int J MS Care
; 23(4): 170-177, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34483756
6.
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Mult Scler Relat Disord
; 27: 101-111, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30368221
7.
A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing.
MDM Policy Pract
; 4(2): 2381468319879134, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31667351
8.
Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
Patient Prefer Adherence
; 12: 1289-1297, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30050291
9.
The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
J Med Econ
; 20(3): 297-302, 2017 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-27822961
10.
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
J Med Econ
; 19(4): 432-42, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26707273
11.
Quantifying Differences in Health Care Consumption for the Management of Multiple Sclerosis Within Privately and Publicly Insured Health Care Programs.
J Manag Care Spec Pharm
; 22(12): 1385-1391, 2016 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-27882831
12.
Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.
J Manag Care Spec Pharm
; 21(3): 210-8b, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25726030
13.
Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates.
Mult Scler Relat Disord
; 3(2): 227-36, 2014 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25878010